Delivery Order SPE2DB22D1002-SPE2DB25FLGL7
- Not listed
- The Defense Logistics Agency awarded a $24,730.89 delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Taltz 80 mg/ml autoinjector. This competitively awarded, firm fixed-price contract carries an ultimate completion date of August 18, 2025, and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply arrangement with DLA. The work will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $3,320.62 to AmerisourceBergen Drug Corp for TALTZ 80 mg/ml autoinjector on August 7, 2025, with ultimate completion by August 8, 2025. This firm fixed price delivery order was competitively awarded without set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. TALTZ is a biologic medication used to treat autoimmune conditions, and this procurement represents a routine...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract valued at $19,605.32 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of Taltz 80 mg/mL autoinjectors. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $999,999,999.00 and awarded solely to AmerisourceBergen Drug Corp, which serves as the primary vehicle for the company to deliver pharmaceutical products and medical...
- The Defense Logistics Agency awarded a $3,320.62 delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for Taltz 80 mg/ml autoinjector medication. This is a firm fixed price, competitively awarded contract with performance completion targeted for August 1, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite...
- The Defense Logistics Agency awarded a $46,054.11 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Taltz 80 mg/mL auto-injector (2-pack) pharmaceutical product. The contract, which is set to be completed by August 1, 2025, will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This competitively awarded delivery order represents a continuation of AmerisourceBergen's ongoing role as a critical pharmaceutical...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of TALTZ 80 mg/ml auto-injector two-packs with a ceiling value of $8,391.13. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Taltz 80 mg/ml autoinjectors with a ceiling value of $4,197.10. This is a firm fixed-price delivery order with an ultimate completion date of July 22, 2025, reflecting a short fulfillment timeline for this pharmaceutical product. The contract utilizes no set-aside designation, indicating it was competitively awarded. AmerisourceBergen's corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Taltz 80 mg/ml auto-injector two-packs, with a firm fixed price ceiling value of $46,869.29. This non-set-aside competitive award is classified as a delivery order with an ultimate completion date of August 12, 2025, and represents a continuation of the vendor's extensive pharmaceutical supply relationship with DLA. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $21,929.06 to AmerisourceBergen Drug Corp for the supply of TALTZ 80 MG/ML Autoinjector, with an ultimate completion date of July 25, 2025. This competitively awarded, non-set-aside contract employs firm fixed pricing and represents a single delivery order transaction. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a $31,833.56 delivery order to AmerisourceBergen Drug Corp for TALTZ 80 mg/mL auto-injector (2-pack) pharmaceutical products, with an ultimate completion date of July 31, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- SPE2DB22D1002Indefinite Delivery Contract
- SPE2DB22D1002-SPE2DB25FLGL7Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Taltz 80 mg/ml autoinjector on August 15, 2025, with a ceiling value of $3,524.56. This is a firm fixed price delivery order with no set-aside designation, indicating competitive procurement. The order is scheduled for completion by August 18, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Taltz is a biologic medication used to treat autoimmune conditions, reflecting the pharmaceutical distribution capabilities AmerisourceBergen provides to federal healthcare systems. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a prime vendor for DLA's pharmaceutical supply chain, AmerisourceBergen supplies a comprehensive range of medications, vaccines, and medical supplies to support military and veteran healthcare systems. The company's status as a major pharmaceutical distributor and its successful track record of meeting federal procurement requirements through open competition positions it as a critical vendor for DLA's medical supply needs across multiple therapeutic domains and global operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.5k | 8/15/25 |